potassium two pore domain channel subfamily K member 17Genealiases: K2p17.1 · TALK-2 · TALK2 · TASK-4 · TASK4
Q-omics provides the consensus-scored KCNK17 profile across patient tissues and cancer cell-line models. KCNK17 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCNK17 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, KCNK17 RNA expression shows 11,888 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUSC, and TGCT as cancer lineages where KCNK17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNK17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNK17 survival associations across molecular data types. KCNK17 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNK17 RNA expression–survival associations across cancer types. High KCNK17 expression shows unfavorable associations in KIRC, KIRP, STAD and ACC, but favorable associations in LUAD and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCNK17 RNA expression.
This table summarizes KCNK17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNK17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNK17 shows lower tumor expression in LUSC, LUAD, LIHC, BRCA and THCA and higher tumor expression in KIRC. The LUSC box plot shows higher KCNK17 RNA expression in normal versus tumor tissue (log2 FC = −2.198, t-test p < 0.001).
This table shows molecular features associated with KCNK17 in patient tissues and cancer cell lines. In patient samples, KCNK17 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNK17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
